Carter Richards
Neurology with Special Qualifications in Child Neurology · San Antonio, TXNPI 1154610707
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 299 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by UCB, Inc. at 24.5% of the total. 2025 is the largest year on record at $2,387, 4.3 times the $560 reported in 2019.
Across 299 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Supernus Pharmaceuticals, Inc.$947
- Corium, LLC$744
- Livanova USA, Inc.$569
- Acadia Pharmaceuticals Inc$550
- Neurelis, Inc.$512
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,933100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 72 | $1,697 |
| Supernus Pharmaceuticals, Inc. | 61 | $947 |
| Corium, LLC | 41 | $744 |
| Livanova USA, Inc. | 17 | $569 |
| Acadia Pharmaceuticals Inc | 17 | $550 |
| Neurelis, Inc. | 15 | $512 |
| Otter Pharmaceuticals, LLC | 12 | $347 |
| Greenwich Biosciences, Inc. | 8 | $329 |
| Jazz Pharmaceuticals Inc. | 7 | $222 |
| Azurity Pharmaceuticals, Inc. | 5 | $136 |
| Tris Pharma Inc | 4 | $116 |
| Upsher-smith Laboratories LLC | 4 | $102 |
| Catalyst Pharmaceuticals, Inc. | 3 | $78 |
| Shire North American Group Inc | 4 | $67 |
| Aucta Pharmaceuticals, Inc. | 8 | $62 |
| Pyros Pharmaceuticals, Inc. | 2 | $59 |
| Biocodex, Inc. | 2 | $57 |
| Eisai Inc. | 3 | $56 |
| Zogenix Inc. | 2 | $47 |
| Springworks Therapeutics, Inc. | 1 | $34 |
| SK Life Science, Inc. | 1 | $29 |
| Aquestive Therapeutics, Inc. | 1 | $25 |
| Merz Pharmaceuticals, LLC | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Biogen | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| OWP Pharmaceuticals, Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Medtronic | 1 | $11 |
| Travere Therapeutics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$325
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$290
- Azstarys$236
- DAYBUE$235
- VNS Therapy$143
- Epidiolex$140
How this compares
$6,933 in reported general payments places this provider in the 80th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium | 13 | $1,755 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in San Antonio
- Jerry TomasovicSan Antonio$5K
- Michael MarshSan Antonio$5K
- Kelly AverillSan Antonio$5K
- Sheldon GrossSan Antonio$4K
- Roy EltermanDallas$5.9M
- Huda ZoghbiHouston$5.5M
- Diana CastroDenton$343K
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
- Michael PerryFort Worth$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.